

# Cardiotoxicity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/C0654C3B19E1EN.html>

Date: May 2024

Pages: 137

Price: US\$ 6,499.00 (Single User License)

ID: C0654C3B19E1EN

## Abstracts

The 7 major cardiotoxicity markets are expected to exhibit a CAGR of 6.22% during 2024-2034.

The cardiotoxicity market has been comprehensively analyzed in IMARC's new report titled "Cardiotoxicity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cardiotoxicity is a medical condition that refers to the toxic effects of certain drugs or other substances on the heart muscle and its function. The severity of cardiotoxicity can vary depending on the specific medication or toxin involved, as well as the dose and duration of exposure. Some common symptoms include shortness of breath, chest pain, palpitations, fatigue, weakness, swelling in the legs and ankles, etc. In severe cases, cardiotoxicity can lead to heart failure, which may present as rapid weight gain, difficulty breathing when lying down, and persistent coughing. The diagnosis of cardiotoxicity typically involves a comprehensive evaluation that includes a review of the patient's medical history, a physical examination, and various diagnostic procedures. These tests consist of an electrocardiogram (ECG) to assess heart rhythm abnormalities, an echocardiogram to examine heart function and structure, and a cardiac MRI to determine heart tissue damage. Additionally, blood tests may also be performed to evaluate cardiac enzyme levels and other markers of heart dysfunction. In some cases, a biopsy of heart tissue may be necessary to confirm the diagnosis of cardiotoxicity.

The escalating utilization of chemotherapy drugs, such as anthracyclines, trastuzumab, tyrosine kinase inhibitors, etc., which damage the heart muscle and lead to heart dysfunction, is primarily driving the cardiotoxicity market. In addition to this, the rising prevalence of associated risk factors that contribute to the development of the disease,

including long-term use of high-dose NSAIDs, chronic alcohol abuse, illicit drug use, genetic predisposition, etc., is further bolstering the market growth. Moreover, the widespread adoption of several medications, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), diuretics, etc., to lower blood pressure, enhance heart function, and reduce fluid buildup in the body is also creating a positive outlook for the market. Besides this, the escalating demand for cardiac rehabilitation programs, which help individuals with cardiotoxicity regain strength and improve cardiovascular function through supervised exercise and other therapies, is acting as a significant growth-inducing factor. Furthermore, the emerging popularity of non-invasive imaging tests, such as cardiac MRI, CT angiography, SPECT imaging, etc., on account of their several advantages over more invasive procedures, including reduced risk of complications and early detection of the ailment, is expected to drive the cardiotoxicity market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the cardiotoxicity market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cardiotoxicity and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cardiotoxicity market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the cardiotoxicity market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the cardiotoxicity market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current cardiotoxicity marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

How has the cardiotoxicity market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they

expected to perform till 2034?

What was the country-wise size of the cardiotoxicity market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the cardiotoxicity market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of cardiotoxicity across the seven major markets?

What is the number of prevalent cases (2018-2034) of cardiotoxicity by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of cardiotoxicity by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with cardiotoxicity across the seven major markets?

What is the size of the cardiotoxicity patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of cardiotoxicity?

What will be the growth rate of patients across the seven major markets?

### Cardiotoxicity: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for cardiotoxicity drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cardiotoxicity market?

What are the key regulatory events related to the cardiotoxicity market?

What is the structure of clinical trial landscape by status related to the cardiotoxicity market?

What is the structure of clinical trial landscape by phase related to the cardiotoxicity market?

What is the structure of clinical trial landscape by route of administration related to the cardiotoxicity market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 CARDIOTOXICITY - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 CARDIOTOXICITY - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 CARDIOTOXICITY - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 CARDIOTOXICITY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 CARDIOTOXICITY - UNMET NEEDS**

## **10 CARDIOTOXICITY - KEY ENDPOINTS OF TREATMENT**

## **11 CARDIOTOXICITY - MARKETED PRODUCTS**

- 11.1 List of Cardiotoxicity Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 CARDIOTOXICITY - PIPELINE DRUGS**

### 12.1 List of Cardiotoxicity Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Drug Name – Company Name

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

## **13. CARDIOTOXICITY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. CARDIOTOXICITY – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 CARDIOTOXICITY - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Cardiotoxicity - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Cardiotoxicity - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Cardiotoxicity - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Cardiotoxicity - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (2024-2034)

#### 15.3.3 Cardiotoxicity - Access and Reimbursement Overview

- 15.4 Market Scenario - Germany
  - 15.4.1 Cardiotoxicity - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Cardiotoxicity - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Cardiotoxicity - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Cardiotoxicity - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Cardiotoxicity - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Cardiotoxicity - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Cardiotoxicity - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Cardiotoxicity - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Cardiotoxicity - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Cardiotoxicity - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Cardiotoxicity - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Cardiotoxicity - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Cardiotoxicity - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Cardiotoxicity - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)

- 15.8.3 Cardiotoxicity - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Cardiotoxicity - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Cardiotoxicity - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Cardiotoxicity - Access and Reimbursement Overview

## **16 CARDIOTOXICITY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 CARDIOTOXICITY MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 CARDIOTOXICITY MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Cardiotoxicity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/C0654C3B19E1EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C0654C3B19E1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

